Related Experiment Video

Updated: Jun 6, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.5K

Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular

Lixia Cheng1, Zhenghui Hu1, Jiawei Gu2

  • 1Department of Medical Genetics and Cell Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) like Meloxicam show promise in treating cancer and cardiovascular disease (CVD). Emerging research suggests these drugs may work through mechanisms beyond inhibiting cyclooxygenase (COX), offering new therapeutic avenues.

Area of Science:

  • Inflammation research
  • Oncology
  • Cardiovascular disease (CVD)

Background:

  • Inflammation is a key factor in cancer and CVD development.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) are traditionally used to manage inflammation.
  • NSAIDs, including Meloxicam, are being investigated for their potential roles in cancer and CVD prevention and treatment.

Purpose of the Study:

  • To explore the potential benefits of NSAIDs, specifically Meloxicam, in oncology and cardiovascular health.
  • To re-evaluate the mechanisms of action for NSAIDs beyond traditional cyclooxygenase (COX) inhibition.
  • To highlight emerging research on COX-independent pathways.

Main Methods:

  • Review of existing scientific literature on NSAIDs, Meloxicam, inflammation, cancer, and CVD.
  • Analysis of studies investigating NSAID mechanisms of action.
  • Synthesis of current understanding regarding COX-dependent and COX-independent effects.

Main Results:

  • NSAIDs, including Meloxicam, may offer benefits in cancer prevention, treatment efficacy, and CVD risk reduction.
  • Traditional NSAID action involves cyclooxygenase (COX) inhibition, reducing prostaglandin (PG) synthesis.
  • Long-term COX inhibition can lead to significant side effects, prompting investigation into alternative mechanisms.

Conclusions:

  • Meloxicam and other NSAIDs may possess therapeutic effects in cancer and CVD through pathways independent of COX inhibition.
  • Further research into these COX-independent mechanisms is crucial for optimizing NSAID use in managing inflammation-related diseases.
  • Understanding these novel mechanisms could lead to improved therapeutic strategies for cancer and cardiovascular conditions.
Keywords:
COX-independent pathwayMeloxicamNSAIDscancercardiovascular disease

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

382
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K